QGE031
Total Payments
$6.8M
Transactions
429
Doctors
19
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $3.7M | 140 | 9 |
| 2019 | $2.0M | 139 | 10 |
| 2018 | $296,840 | 91 | 1 |
| 2017 | $735,020 | 59 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.7M | 409 | 99.5% |
| Consulting Fee | $34,829 | 9 | 0.5% |
| Food and Beverage | $661.76 | 11 | 0.0% |
Payments by Type
Research
$6.7M
409 transactions
General
$35,491
20 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI CENTER RANDOMIZED DOUBLE BLIND ACTIVE AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LIGELIZUMAB QGE031 IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA CSU IN ADOLESCENTS AND ADULTS INADEQUATELY CONTROLLED WITH H1 ANTIHIS | Novartis Pharmaceuticals Corporation | $5.4M | 0 |
| LONG TERM OPEN LABEL SAFETY AND EFFICACY STUDY OF QGE031 IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA CSU | Novartis Pharmaceuticals Corporation | $584,240 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVE CONTROLLED PHASE 2B DOSE FINDING STUDY OF QGE031 AS ADD ON THERAPY TO INVESTIGATE THE EFFICACY AND SAFETY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA CSU | Novartis Pharmaceuticals Corporation | $276,559 | 0 |
| A MULTI-CENTER, DOUBLE-BLINDED AND OPEN-LABEL EXTENSION STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LIGELIZUMAB AS RETREATMENT, SELF-ADMINISTERED THERAPY AND MONOTHERAPY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO COMPLETED STUDIES CQGE031C2302, CQGE03 | Novartis Pharmaceuticals Corporation | $141,424 | 0 |
| A PHASE I DOUBLE BLIND STUDY TO INVESTIGATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE DOSES OF QGE031 ADMINISTERED VIA SUBCUTANEOUS INJECTION OR INFUSION USING DIFFERENT DELIVERY SYSTEMS IN HEALTHY VOLUNTEERS | Novartis Pharmaceuticals Corporation | $119,776 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND ACTIVE AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LIGELIZUMAB QGE031 IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA CSU IN ADOLESCENTS AND ADULTS INADEQUATELY CONTROLLED WITH H1 ANTIHISTAMINES | Novartis Pharmaceuticals Corporation | $93,600 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND ACTIVE AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LIGELIZUMAB QGE031 IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA CSU IN ADOLESCENTS AND ADULTS INADEQUATELY CONTROLLED WITH H1 ANTIHIS | NOVARTIS PHARMACEUTICALS CORPORATION | $90,871 | 0 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B DOSE-FINDING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LIGELIZUMAB (QGE031) IN ADOLESCENT PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU) | Novartis Pharmaceuticals Corporation | $13,199 | 0 |
| A MULTI-CENTER, DOUBLE-BLINDED AND OPEN-LABEL EXTENSION STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LIGELIZUMAB AS RETREATMENT, SELF-ADMINISTERED THERAPY AND MONOTHERAPY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS WHO COMPLETED STUDIES CQGE031C2302, CQGE03 | NOVARTIS PHARMACEUTICALS CORPORATION | $8,780 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVE CONTROLLED STUDY WITH EXPLORATORY DOSE RANGING TO INVESTIGATE THE EFFICACY AND SAFETY OF 16 WEEKS TREATMENT WITH SUBCUTANEOUS QGE031 IN ASTHMA PATIENTS NOT ADEQUATELY CONTROLLED WITH HIGH DOSE INHALED CORTICOSTEROIDS AND LONG ACTING B2 AGONISTS | Novartis Pharmaceuticals Corporation | $6,906 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF 52 WEEKS TREATMENT WITH QGE031 SC IN ASTHMA PATIENTS NOT ADEQUATELY CONTROLLED BY MEDIUM OR HIGH DOSE ICS PLUS LABA WITH OR WITHOUT OCS | Novartis Pharmaceuticals Corporation | $2,884 | 0 |
Top Doctors Receiving Payments for QGE031
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Fort Worth, TX | $6.7M | 409 |
| , MD | Pain Medicine | Louisville, KY | $4,320 | 1 |
| , M.D., PH.D | Dermatology | Aventura, FL | $4,320 | 1 |
| , MD | Clinical & Laboratory Dermatological Immunology | Los Angeles, CA | $4,320 | 1 |
| Boni Elewski | Dermatology | Birmingham, AL | $4,320 | 1 |
| , MD | Internal Medicine | Cincinnati, OH | $3,924 | 1 |
| , M.D.M.D | Allergy & Immunology | North Charleston, SC | $3,815 | 1 |
| , MD | Allergy & Immunology | Chestnut Hill, MA | $3,270 | 1 |
| , MD | Allergy & Immunology | Phoenix, AZ | $3,270 | 1 |
| , MD | Allergy | Coral Gables, FL | $3,270 | 1 |
| , MD | Allergy & Immunology | Tampa, FL | $115.71 | 1 |
| , M.D | Allergy & Immunology | Tampa, FL | $115.71 | 1 |
| , M.D | Allergy & Immunology | Tampa, FL | $115.71 | 1 |
| Jack Parrino | — | Tampa, FL | $115.71 | 1 |
| Lyndon Mansfield | — | El Paso, TX | $71.09 | 1 |
| , M.D | Internal Medicine | San Diego, CA | $61.83 | 2 |
| , MD | Allergy | Los Angeles, CA | $22.18 | 1 |
| , MD | Allergy & Immunology | San Jose, CA | $18.10 | 1 |
| , M.D | Pulmonary Disease | Gastonia, NC | $12.86 | 1 |
| , MD | Dermatology | Gastonia, NC | $12.86 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.8M
- Total Doctors 19
- Transactions 429
About QGE031
QGE031 is a drug associated with $6.8M in payments to 19 healthcare providers, recorded across 429 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $3.7M was paid across 140 transactions to 9 doctors.
The most common payment nature for QGE031 is "Unspecified" ($6.7M, 99.5% of total).
QGE031 is associated with 11 research studies, including "A MULTI CENTER RANDOMIZED DOUBLE BLIND ACTIVE AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LIGELIZUMAB QGE031 IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA CSU IN ADOLESCENTS AND ADULTS INADEQUATELY CONTROLLED WITH H1 ANTIHIS" ($5.4M).